146 related articles for article (PubMed ID: 35366926)
21. Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer.
Bergamin S; Eade T; Kneebone A; Booth J; Hsiao E; Schembri GP; Szymura K; Le A; Kwong C; Brown C; Hunter J; Hruby G
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1172-1178. PubMed ID: 32659332
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC
Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102
[TBL] [Abstract][Full Text] [Related]
23. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
Dixit A; Tang C; Bydder S; Kedda MA; Vosikova E; Bharat C; Gill S
J Med Radiat Sci; 2017 Sep; 64(3):180-187. PubMed ID: 28271639
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study.
Alayed Y; Loblaw A; Chu W; Al-Hanaqta M; Chiang A; Jain S; Chung H; Vesprini D; Morton G; Ravi A; Davidson M; Deabreu A; Mamedov A; Zhang L; Erler D; Cheung P
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1066-1073. PubMed ID: 31002941
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer.
Parikh NR; Kishan AU; Kane N; Diaz-Perez S; Ganapathy E; Nazarian R; Felix C; Mathis C; Bradley M; Sachdeva A; Wyatt B; Basehart V; Zomorodian N; Lin L; King CR; Kupelian PA; Rettig MB; Steinberg ML; Cao M; Knudsen BS; Elashoff D; Schaue D; Reiter RE; Nickols NG
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):930-935. PubMed ID: 32562839
[TBL] [Abstract][Full Text] [Related]
26. Potency preservation following stereotactic body radiation therapy for prostate cancer.
Obayomi-Davies O; Chen LN; Bhagat A; Wright HC; Uhm S; Kim JS; Yung TM; Lei S; Batipps GP; Pahira J; McGeagh KG; Collins BT; Kowalczyk K; Bandi G; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Nov; 8():256. PubMed ID: 24180317
[TBL] [Abstract][Full Text] [Related]
27. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.
Sood S; Ju AW; Wang H; Lei S; Uhm S; Zhang G; Suy S; Carroll J; Lynch J; Dritschilo A; Collins SP
Radiat Oncol; 2013 Aug; 8():197. PubMed ID: 23937800
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes.
Hwang ME; Mayeda M; Liz M; Goode-Marshall B; Gonzalez L; Elliston CD; Spina CS; Padilla OA; Wenske S; Deutsch I
Radiat Oncol; 2019 Aug; 14(1):136. PubMed ID: 31375119
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
31. Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life.
Musunuru HB; D'Alimonte L; Davidson M; Ho L; Cheung P; Vesprini D; Liu S; Chu W; Chung H; Ravi A; Deabreu A; Zhang L; Commisso K; Loblaw A
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1438-1447. PubMed ID: 30071295
[TBL] [Abstract][Full Text] [Related]
32. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.
Jiang P; Krockenberger K; Vonthein R; Tereszczuk J; Schreiber A; Liebau S; Huttenlocher S; Imhoff D; Balermpas P; Keller C; Dellas K; Baumann R; Rödel C; Hildebrandt G; Jünemann KP; Merseburger AS; Katz A; Ziegler A; Blanck O; Dunst J
Radiat Oncol; 2017 Aug; 12(1):138. PubMed ID: 28821268
[TBL] [Abstract][Full Text] [Related]
33. Prospective validation of stringent dose constraints for prostatic stereotactic radiation monotherapy: results of a single-arm phase II toxicity-oriented trial.
Nguyen P; Harzée L; Retif P; Joseph S; Vogin G; Nickers P
Strahlenther Onkol; 2021 Nov; 197(11):1001-1009. PubMed ID: 34424351
[TBL] [Abstract][Full Text] [Related]
34. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
Front Oncol; 2020; 10():555. PubMed ID: 32432033
[No Abstract] [Full Text] [Related]
35. Stereotactic body radiation therapy with simultaneous integrated boost for prostate cancer: does MRI-targeted biopsy alter the boost field?
Fang AM; Burns ZR; Nocera AP; Cardan RA; Nix JW; Porter KK; McDonald AM; Rais-Bahrami S
Can J Urol; 2021 Oct; 28(5):10817-10823. PubMed ID: 34657654
[TBL] [Abstract][Full Text] [Related]
36. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience.
Mercado C; Kress MA; Cyr RA; Chen LN; Yung TM; Bullock EG; Lei S; Collins BT; Satinsky AN; Harter KW; Suy S; Dritschilo A; Lynch JH; Collins SP
Front Oncol; 2016; 6():114. PubMed ID: 27200300
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic body radiotherapy for organ-confined prostate cancer.
Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
BMC Urol; 2010 Feb; 10():1. PubMed ID: 20122161
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic Body Radiation Therapy for Prostate Cancer: An Institutional Experience Using MRI-guided Treatment Planning.
Waheed NL; Yoder AK; Van Wyhe RD; Carpenter SL
Cureus; 2018 May; 10(5):e2590. PubMed ID: 30009104
[TBL] [Abstract][Full Text] [Related]
39. Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and Prostate-Specific Antigen Kinetics in Localized Prostate Cancer.
Tambas M; Agaoglu F; Iribas A; Guveli M; Dizdar Y; Okutan M; Sahin D; Tenekeci N; Darendeliler E
Value Health Reg Issues; 2016 Sep; 10():91-99. PubMed ID: 27881285
[TBL] [Abstract][Full Text] [Related]
40. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
